217 related articles for article (PubMed ID: 12490770)
1. Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide.
Pini S; Amador XF; Dell'Osso L; Baldini Rossi N; Cassano P; Savino M; Cassano GB
Int Clin Psychopharmacol; 2003 Jan; 18(1):15-21. PubMed ID: 12490770
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on paroxetine in psychiatric disorders in adults.
Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy for anxiety and comorbid alcohol use disorders.
Ipser JC; Wilson D; Akindipe TO; Sager C; Stein DJ
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD007505. PubMed ID: 25601826
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
7. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
[TBL] [Abstract][Full Text] [Related]
8. The use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial.
Misri S; Reebye P; Corral M; Milis L
J Clin Psychiatry; 2004 Sep; 65(9):1236-41. PubMed ID: 15367052
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
Silverstone PH; Salinas E
J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
[TBL] [Abstract][Full Text] [Related]
10. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.
Pollack MH; Zaninelli R; Goddard A; McCafferty JP; Bellew KM; Burnham DB; Iyengar MK
J Clin Psychiatry; 2001 May; 62(5):350-7. PubMed ID: 11411817
[TBL] [Abstract][Full Text] [Related]
11. An open-label trial of nefazodone in high comorbidity panic disorder.
DeMartinis NA; Schweizer E; Rickels K
J Clin Psychiatry; 1996 Jun; 57(6):245-8. PubMed ID: 8666561
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
Musselman DL; Somerset WI; Guo Y; Manatunga AK; Porter M; Penna S; Lewison B; Goodkin R; Lawson K; Lawson D; Evans DL; Nemeroff CB
J Clin Psychiatry; 2006 Feb; 67(2):288-96. PubMed ID: 16566626
[TBL] [Abstract][Full Text] [Related]
13. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
Weihs KL; Settle EC; Batey SR; Houser TL; Donahue RM; Ascher JA
J Clin Psychiatry; 2000 Mar; 61(3):196-202. PubMed ID: 10817105
[TBL] [Abstract][Full Text] [Related]
14. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
[TBL] [Abstract][Full Text] [Related]
15. Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review.
Bourin M
Hum Psychopharmacol; 2003 Apr; 18(3):185-90. PubMed ID: 12672169
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group.
Ravindran AV; Judge R; Hunter BN; Bray J; Morton NH
J Clin Psychiatry; 1997 Mar; 58(3):112-8. PubMed ID: 9108813
[TBL] [Abstract][Full Text] [Related]
18. Paroxetine response and tolerability among ethnic minority patients with mood or anxiety disorders: a pooled analysis.
Roy-Byrne PP; Perera P; Pitts CD; Christi JA
J Clin Psychiatry; 2005 Oct; 66(10):1228-33. PubMed ID: 16259535
[TBL] [Abstract][Full Text] [Related]
19. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.
Rosenthal M
J Clin Psychiatry; 2003 Oct; 64(10):1245-9. PubMed ID: 14658975
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.
Liebowitz MR; Stein MB; Tancer M; Carpenter D; Oakes R; Pitts CD
J Clin Psychiatry; 2002 Jan; 63(1):66-74. PubMed ID: 11838629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
